BackEucrates Biomedical Acquisition Overview

Eucrates Biomedical Acquisition Total Liabilities

Eucrates Biomedical Acquisition's total liabilities is $3.9M.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$3.95M
↓ 31.90% YoYΔ $-1.85M vs prior year quarter

Peer trimmed avg / median

Loading

Eucrates Biomedical Acquisition Total Liabilities History

Loading

Eucrates Biomedical Acquisition vs. peers: Total Liabilities Comparison

Loading

Eucrates Biomedical Acquisition Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Eucrates Biomedical Acquisition (EUCR) FAQ

The latest total liabilities for EUCR is $3.9M as of December 2022. That compares with $5.8M in the prior-year period — down 31.9% year over year. Investors often review this figure alongside Eucrates Biomedical Acquisition's historical trend and sector peers before judging valuation or financial health.

Over the past year, EUCR's total liabilities moved from $5.8M to $3.9M — a 31.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Eucrates Biomedical Acquisition's operating scale or balance-sheet position.

A total liabilities figure of $3.9M for EUCR is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting EUCR's total liabilities ($3.9M), review year-over-year change from $5.8M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.